Fat Burner Ranking 2026
The lists of "fat burning" substances have one common drawback: it is not known how they were ranked.
The lists of “fat burning” substances have one common drawback: it is not known how they were ranked. This ranking reverses the order of questions and starts with an explicit methodology, because without it the list itself remains unverifiable.
To state the conclusion upfront: the order in this list reflects the volume and quality of the available literature, not potency, safety or usefulness. Some of the compounds discussed have been tested in phase three studies involving thousands of people, while some have never been tested in humans. Treating them as items on a single “effectiveness” list would be a mistake – that’s why we divide them into levels of evidence.
Materials offered under the names of the substances discussed are research reagents and are not intended for use in humans or animals – they are not substitutes for medicinal products, even if they contain the same active substance. The data cited come from the scientific literature: from cell and animal models to clinical trials conducted on registered medicinal products.
Methodology – how this ranking was created
The substances are ordered according to level of available evidence, adopting the hierarchy used in the assessment of medical literature. The criterion for assigning a compound to a level is singular and verifiable: what is the highest-level study conducted for a given compound.
| Level | Assignment criterion | What does it mean |
|---|---|---|
| Level I | randomized clinical trials phase II-III with involving humans | known effect, known adverse effect profile |
| Tier II | smaller-scale human studies or discontinued development program | data exist but are limited or incomplete |
| Tier III | animal models only cellular | no data on effects in humans |
What this list doesn’t do:
- Does not rank by potency. Higher level of evidence means better documentation, not stronger effect.
- Does not rank by safety. The safety profile is a separate axis – a Level III compound is not “safer”, but untested.
- Does not take into account legal status as a ranking criterion. The status is provided separately for each item, because it is independent of the quality of evidence.
- Does not constitute a recommendation. All materials discussed are research reagents.
The mechanisms of action of each group are discussed in detail in the evergreen guide to effective fat burners. This material serves a different purpose – it is an annual review of the state of evidence, supplemented as new publications become available.
Level I – compounds with phase II and III clinical trials
Common note to this group: the studies cited were conducted on registered products medicinal products, in populations diagnosed with obesity or type 2 diabetes and under medical supervision. The research reagent with the same name of the active substance is not a substitute for the medicinal product, and the results of these trials do not describe its use.
Semaglutide
GLP-1 receptor agonist. The best documented relationship on the entire list. The SELECT trial, which included obese people without diabetes, assessed the effect of semaglutide on cardiovascular events (Lincoff et al., 2023, PMID 37952131) — an endpoint that is tougher than weight loss alone body.
Status: active substance of registered medicinal products subject to medical prescription. The research reagent is not a substitute.
Tirzepatide – a dual GLP-1/GIP agonist
It acts on two incretin receptors simultaneously. The SURPASS-2 trial compared it head-to-head with semaglutide in people with type 2 diabetes (Frías et al., 2021, PMID 34170647). Efficacy in the treatment of obesity was assessed in the SURMOUNT-1 (Jastreboff et al., 2022, PMID 35658024) and SURMOUNT-2 studies, in people with obesity and type 2 diabetes (Garvey et al., 2023, PMID 37385275).
Status: active substance of registered medicinal products.
Retatrutide
Triple agonist of GLP-1, GIP and glucagon receptors. The results of the study phase 2 in obesity were published in New England Journal of Medicine (Jastreboff et al., 2023, PMID 37366315).
It is worth noting the difference from the two previous items: this phase two study, smaller in size than the semaglutide and tirzepatyduregistration programs. Retatrutide is not an approved medicinal product in any jurisdiction — its clinical development program is ongoing.
Level II – compounds with limited human data
L-carnitine
Participates in the transport of long-chain fatty acids to the mitochondria. It was the only level II item to undergo meta-analyses of randomized trials with dose-response analysis: the extensive study included 37 controlled studies (Talenezhad et al., 2020, PMID 32359762), and the earlier systematic review with meta-analysis published in Obesity Reviews (Pooyandjoo et al., 2016, PMID 27335245).
Let’s note something that ranking lists usually miss: well-documented does not mean strong. L-carnitine has the best quality of evidence among level II items, and the effects observed in meta-analyses are small. These are two independent pieces of information.
Yohimbine
An alkaloid with antagonistic activity against α2-adrenergic receptors – a mechanism related to the inhibition of the pathway limiting lipolysis. It was studied, among others, in football players (Ostojic, 2006, PMID 17214405). The same mechanism is responsible for the risk profile: the anxiogenic effect of yohimbine has been demonstrated in healthy volunteers (Mattila et al., 1988, PMID 3153710). We discuss this compound in more detail in a separate material about yohimbine.
Fragment hGH 176–191 and AOD-9604
Fragment 176–191 is the C-terminal section of the growth hormone molecule, isolated on the basis of the hypothesis that the lipolytic activity of hGH can be separated from its effect on growth and the IGF-1 axis. An analogue of this fragment, AOD-9604, was being developed as a metabolic drug candidate and has undergone early phase testing (Wilding, 2004, PMID 15134286). The program has not ended registration.
Anti-Doping Notice: growth hormone and its fragments are included in the category S2 WADA Prohibited List and are prohibited at all times.
Tesofensine
Monoamine reuptake inhibitor, being developed as an anti-obesity drug (Bello and Zahner, 2009, PMID 19777399). The context for the entire class of centrally acting drugs – along with the history of withdrawals in this class – is summarized in the review (Coulter et al., 2018, PMID 30014268).
This item requires a clear disclaimer: Central Mechanism Substances have a history of withdrawals in this field due to adverse effects, mainly cardiovascular and psychiatric. The cited review discusses this story directly. Tesofensine is not a registered medicinal product.
Level III – preclinical models only
For compounds in this group, no human clinical trials have been published. No human efficacy, pharmacokinetics or safety data exist.
MOTS-c
Peptide encoded by the mitochondrial genome. The work published in Cell Metabolism described its effect on metabolic homeostasis, obesity and insulin resistance in a mouse model (Lee et al., 2015, PMID 25738459). The state of the art is summarized in a subsequent review (Zheng et al., 2023, PMID 36761202).
SLU-PP-332
Synthetic ERR (estrogen receptor-related receptor) agonist investigated in the context of metabolic (Billon et al., 2024, PMID 37739806). Work on this class of compounds also includes newer molecules evaluated for aerobic capacity (Billon et al., 2026, PMID 41421047) and cardiac applications (Xu et al., 2024, PMID 37961903).
The term “exercise mimetic” that accompanies this group describes a research field in animal models with no proven effect in humans. The compound itself, its model data and its status on the 2026 and 2027 Lists are covered in a separate article on SLU-PP-332.
Summary table
| Substance | Level | Mechanism | Status | WADA |
|---|---|---|---|---|
| Semaglutide | I | agonist GLP-1 | active substance of the drug | Monitoring Program |
| Tirzepatid | I | GLP-1 and GIP agonist | active substance of the drug | Program Monitoring |
| Retatrutyd | I (phase II) | GLP-1, GIP, glucagon agonist | no registration | S0 — non-approved substances; prohibited at all times |
| L-carnitine | II | fatty acid transport | food ingredient | not on the List |
| Yohimbine | II | α2 antagonist | restricted status in the EU | not on the List |
| hGH fragment / AOD-9604 | II | lipolytic hGH fragment | no registration | S2 |
| Tesofensine | II | monoamine uptake inhibitor | not registered | S6 — stimulants; prohibited in competition |
| MOTS-c | III | mitochondrial peptide | none registration | S4.4 — metabolic modulators; prohibited at all times |
| SLU-PP-332 | III | ERR agonist | not registered | S0 — non-approved substances; prohibited at all times |
A missing name on the Prohibited List does not settle a compound’s status. Compounds without marketing authorisation in any country, such as retatrutide or SLU-PP-332, are covered by class S0 (non-approved substances), and in many classes the ban also extends to substances with a similar chemical structure or similar biological effect. In Poland, anti-doping regulations are applied by the Polish Anti-Doping Agency (POLADA), and amateur competitors are also subject to control. The current status should always be verified in the current version of the List.
What this list does not determine
- It does not determine the effectiveness in a healthy person. Level I studies were conducted in populations diagnosed with obesity or diabetes.
- It does not determine the safety. For level III the safety profile in humans does not exist – it is not favorable or unfavorable, it simply has not been established.
- Does not take into account interactions. Putting several substances together multiplies the number of unknowns; a case of simultaneous abuse of a PPAR-δ agonist and an androgen receptor modulator (SARM) has been described (Kintz et al., 2021, PMID 34678947).
- Does not replace energy deficit. None of the described mechanisms operate independently of the balance energy.
Frequently asked questions
What is this ranking based on?
By level of available evidence – the highest type of study that a given compound has been subjected to. This is not ranked by potency, safety or suitability.
Does ranking higher mean stronger?
No. It means better documentation. L-carnitine has a higher quality of evidence than most lists, and the observed effects are small – these are two independent pieces of information.
Are Level III compounds safer because they are “natural” or “mitochondrial”?
No. Level III means no studies in humans, and therefore no established safety profile. The endogenous origin of the molecule does not indicate the safety of external administration.
Is the research reagent the same as the drug of the same name?
No. Clinical trials cited at Level I were conducted on registered medicinal products, under medical supervision, in specific populations. The research reagent is not a substitute for the medicinal product.
Why does the summary not provide doses?
Because there is no established dosage for most of the substances discussed – their determination is the result of a registration process that they have not undergone. For registered substances, the decision of the attending physician is decisive, not the article.
Summary
A list of substances tested in the context of adipose tissue metabolism only makes sense if it explicitly provides a ranking criterion. This is based on the level of available evidence, resulting in three clearly distinct groups. Level I includes incretin receptor agonists – semaglutide and tirzepatide with registration programs and retatrutyd with a published phase 2 study. Level II are compounds with but limited human data: L-carnitine with meta-analyses of randomized trials and small effects, yohimbine whose mechanism accounts for both its effects and risk profile, the discontinued AOD-9604 program, and tesofensine from a class with a documented history of withdrawals. Level III — MOTS-c and SLU-PP-332 — are compounds without any human testing. A higher ranking means better documentation, not stronger performance or greater security; these are three independent assessment axes, which ranking lists usually do not separate.
Product documentation
Research material cards along with batch analytical documentation are available in the category burners. Materials intended for research use only.
Bibliography
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Garvey WT, Frías JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315
- Talenezhad N, Mohammadi M, Ramezani-Jolfaie N, Mozaffari-Khosravi H, Salehi-Abargouei A. Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis. Clin Nutr ESPEN. 2020;37:9-23. PMID: 32359762
- Pooyandjoo M, Nouhi M, Shab-Bidar S, Djafarian K, Olyaeemanesh A. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2016;17(10):970-976. PMID: 27335245
- Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med. 2006;14(4):289-299. PMID: 17214405
- Mattila M, Seppälä T, Mattila MJ. Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Psychopharmacol. 1988;3(3):215-229. PMID: 3153710
- Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436-440. PMID: 15134286
- Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009;10(10):1105-1116. PMID: 19777399
- Coulter AA, Rebello CJ, Greenway FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. 2018;78(11):1113-1132. PMID: 30014268
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
- Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023;14:1120533. PMID: 36761202
- Billon C, Schoepke E, Avdagic A, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240. PMID: 37739806
- Billon C, Appourchaux K, Coté I, Burris TP. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026;393(1):103787. PMID: 41421047
- Xu W, Billon C, Li H, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024;149(3):227-250. PMID: 37961903
- Kintz P, Gheddar L, Paradis C, et al. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR-delta) and Selective Androgen Receptor Modulator (SARM) Abuse. Toxics. 2021;9(10):251. PMID: 34678947